Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Anaplastic Astrocytoma, Glioblastoma
Interventions: trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine; Drug · Device · Procedure
Lead sponsor: Isarna Therapeutics GmbH; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Edison, New Jersey • Mineola, New York • Rochester, New York

Conditions: Alzheimer Disease, Gut Biome
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 65 Years to 90 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Anemia, Mortality
Interventions: Early anemia diagnosis and treatment, No change from normal routine; Other
Lead sponsor: Fresenius Medical Care North America; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 42
States / cities: Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more

Conditions: Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
Interventions: Faricimab Injection, sham treatment; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Intractable Pain
Interventions: Intraspinal Gabapentin; Drug
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 14
States / cities: Little Rock, Arkansas • Napa, California • Sarasota, Florida + 11 more

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more

Conditions: Asthma, Bronchospasm
Interventions: albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Denver, Colorado • Englewood, Colorado • Lakewood, Colorado

Conditions: Multiple Myeloma
Interventions: JCARH125, JCARH125 + anakinra; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more

Conditions: Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
Interventions: Nitrous oxide gas for inhalation, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Wrinkle Appearance, Skin Pigment, Erythema, Side Effect, Microbiome, Lipidome
Interventions: Acetyl Zingerone Topical Cream, Topical cream; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 30 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Participants
Interventions: BMS-986308, Placebo (for BMS-986308), Furosemide; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: GSBR-1290, Placebo; Drug · Other
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Osteoarthritis Pain
Interventions: ACP-044 Dose A, ACP-044 Dose B, Placebo; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 28 more

Conditions: Labor Pain
Interventions: Intracutaneous injections; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pediatric Obesity, Insulin Resistance
Interventions: High-fat Challenge; Dietary Supplement
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 8 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Obesity or Overweight, Type 2 Diabetes
Interventions: Petrelintide, Placebo; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Manassas, Virginia

Conditions: Pulmonary Arterial Hypertension (PAH)
Interventions: Allogeneic Human Cardiosphere-Derived Stem Cells, Placebo; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Injuries, Spinal Cord, CVA (Cerebrovascular Accident), Traumatic Brain Injury, MS (Multiple Sclerosis), Muscle Spasticity, Cerebral Palsy, Spastic
Interventions: Prometra II Programmable Pump - Flowonix Medical; Device
Lead sponsor: Culicchia Neurological Clinic; Other
Eligibility: 22 Years to 85 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Marrero, Louisiana

Conditions: Cognitive Function
Interventions: Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 4.1 Usage, Clarity Active Study Product 4.2 Usage, Clarity Active Study Product 4.3 Usage, Placebo Control Form 1, Placebo Control Form 2, Placebo Control Form 3, Placebo Control Form 4, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 4,826 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 19
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Pregnancy, Preeclampsia (PE)
Interventions: 17 OHPC; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Tobacco Use, Opioid Use Disorder, Tobacco-Related Disorders
Interventions: E-cigarette, Control/Standard Advice; Other · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 50 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: OIC
Interventions: Relistor Injectable Product, Docusate Calcium, Bisacodyl, Milk of magnesia, Magnesium citrate, Senna, Enema; Drug
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Plaque Psoriasis
Interventions: 188-0551 Solution, Vehicle Solution; Drug
Lead sponsor: Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Search by objective public record fields.

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

N2O for Acute Suicidality and Depression in the ED

Cosmetic Effects of Topical Acetyl Zingerone

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Intracutaneous Sterile Water Injections

High-fat Meal Challenge in Pediatrics

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)

Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes

A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients

Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia

E-cigarette Switching Older Adults

RELISTOR's Effects on Opioid-Induced Constipation

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)